FENC
Fennec Pharmaceuticals Inc. NASDAQ Listed Sep 15, 2017$6.89
Mkt Cap $196.9M
52w Low $5.65
29.0% of range
52w High $9.92
50d MA $6.99
200d MA $7.96
P/E (TTM)
-18.2x
EV/EBITDA
-26.7x
P/B
5.3x
Debt/Equity
0.0x
ROE
-27.5%
P/FCF
-17.6x
RSI (14)
—
ATR (14)
—
Beta
0.93
50d MA
$6.99
200d MA
$7.96
Avg Volume
166.9K
Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.
68 TW Alexander Drive · Research Triangle Park, NC 27709 · US
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 24, 2026 | AMC | 0.03 | -0.11 | -466.7% | 6.02 | -1.5% | +2.5% | +5.5% | -9.2% | -2.4% | +6.6% | — |
| Nov 13, 2025 | AMC | -0.08 | -0.02 | +75.0% | 7.69 | +13.8% | +2.2% | +11.3% | +0.0% | -6.5% | -4.2% | — |
| Aug 14, 2025 | AMC | -0.06 | -0.11 | -83.3% | 8.53 | +1.1% | -2.0% | -1.9% | -3.5% | +2.1% | +1.1% | — |
| May 13, 2025 | AMC | -0.12 | -0.04 | +66.7% | 6.48 | +0.5% | -2.3% | +3.5% | +4.4% | +11.8% | +6.8% | — |
| Mar 10, 2025 | AMC | 0.56 | -0.06 | -110.7% | 6.11 | +2.3% | +4.7% | +1.6% | -5.7% | +6.2% | -2.9% | — |
| Nov 7, 2024 | AMC | -0.13 | -0.21 | -61.5% | 4.36 | -1.1% | -1.6% | -0.7% | -0.7% | +5.9% | -1.8% | — |
| Aug 13, 2024 | AMC | 0.06 | -0.20 | -433.3% | 5.85 | +1.0% | -8.9% | +4.7% | -0.4% | +2.9% | -2.1% | — |
| May 14, 2024 | AMC | 0.26 | 0.47 | +80.8% | 7.34 | +6.7% | -4.9% | +2.0% | -1.1% | +3.8% | -2.6% | — |
| Mar 21, 2024 | AMC | -0.02 | -0.10 | -400.0% | 11.07 | +0.8% | -2.4% | +1.9% | -1.0% | +1.8% | +0.3% | — |
| Nov 6, 2023 | AMC | -0.11 | -0.07 | +36.4% | 7.96 | +1.3% | +2.5% | -6.6% | +1.7% | -2.2% | +3.8% | — |
| Aug 3, 2023 | AMC | -0.18 | -0.21 | -16.7% | 8.01 | -1.1% | +0.2% | +1.1% | +0.4% | +0.6% | +2.1% | — |
| May 11, 2023 | AMC | -0.21 | -0.23 | -9.5% | 7.87 | +1.1% | -4.6% | +1.7% | -3.4% | +2.2% | -1.6% | — |
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apr 16 | Wedbush | Maintains | Outperform → Outperform | — | $6.50 | $6.47 | -0.5% | -3.1% | +7.8% | -0.9% | -2.8% | +2.1% |
| Aug 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.08 | $8.07 | -0.1% | +1.1% | +6.0% | -0.1% | +0.3% | +4.1% |
| Aug 15 | Craig-Hallum | Maintains | Buy → Buy | — | $8.53 | $8.62 | +1.1% | -2.0% | -1.9% | -3.5% | +2.1% | +1.1% |
| May 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.65 | $8.10 | +5.9% | +6.8% | +1.5% | -3.9% | -1.3% | +3.3% |
| May 14 | Craig-Hallum | Maintains | Buy → Buy | — | $6.48 | $6.51 | +0.5% | -2.3% | +3.5% | +4.4% | +11.8% | +6.8% |
| Mar 11 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $6.11 | $6.25 | +2.3% | +4.7% | +1.6% | -5.7% | +6.2% | -2.9% |
| Dec 17 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.95 | $5.86 | -1.5% | +2.0% | -6.8% | +3.2% | +2.6% | +3.7% |
| Aug 22 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $5.63 | $5.73 | +1.8% | -2.3% | +3.6% | +2.5% | -2.9% | -4.1% |
| Aug 14 | Craig-Hallum | Maintains | Buy → Buy | — | $5.85 | $5.91 | +1.0% | -8.9% | +4.7% | -0.4% | +2.9% | -2.1% |
| May 15 | Craig-Hallum | Maintains | Buy → Buy | — | $7.34 | $7.83 | +6.7% | -4.9% | +2.0% | -1.1% | +3.8% | -2.6% |
| May 15 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.34 | $7.83 | +6.7% | -4.9% | +2.0% | -1.1% | +3.8% | -2.6% |
| Apr 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $10.77 | $10.91 | +1.3% | +1.3% | -2.0% | +1.3% | +0.6% | -2.0% |
| Mar 18 | Craig-Hallum | Maintains | Buy → Buy | — | $9.94 | $10.75 | +8.1% | +11.4% | -0.5% | +0.5% | +0.0% | -2.4% |
| Aug 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.01 | $7.92 | -1.1% | +0.2% | +1.1% | +0.4% | +0.6% | +2.1% |
| Jun 21 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.55 | $9.44 | -1.2% | +2.8% | -3.5% | -5.5% | -0.9% | +0.6% |
| Apr 6 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $8.48 | $8.55 | +0.8% | +0.1% | +6.0% | -0.8% | -3.7% | -0.3% |
| Apr 4 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.22 | $8.22 | +0.0% | +2.1% | +1.1% | +0.1% | +6.0% | -0.8% |
| Mar 31 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.55 | $8.70 | +1.8% | -2.7% | -1.2% | +2.1% | +1.1% | +0.1% |
| Jan 26 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $9.95 | $9.90 | -0.5% | -1.2% | -3.8% | -0.4% | +6.3% | +2.0% |
| Nov 22 | Cantor Fitzgerald | Upgrade | Neutral → Overweight | — | $8.71 | $9.00 | +3.3% | +9.4% | -0.2% | +0.0% | +1.1% | +1.5% |
| Oct 20 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.20 | $8.39 | +2.3% | +1.2% | +0.0% | -0.8% | +0.5% | +0.2% |
| Sep 26 | Wedbush | Maintains | Outperform → Outperform | — | $7.83 | $7.78 | -0.6% | -8.3% | +1.9% | +1.9% | +7.8% | +0.7% |
| Sep 7 | Capital One | Maintains | Overweight → Overweight | — | $7.35 | $7.40 | +0.7% | -3.3% | -3.2% | -7.8% | +3.0% | +2.0% |
| Jun 3 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $7.46 | $6.92 | -7.2% | -0.9% | +1.1% | -5.2% | -1.6% | +1.1% |
| Apr 21 | Craig-Hallum | Maintains | Buy → Buy | — | $6.22 | $6.42 | +3.2% | +11.1% | -0.4% | -0.3% | +2.5% | -2.3% |
| Apr 19 | Maxim Group | Maintains | Buy → Buy | — | $6.27 | $6.51 | +3.8% | -0.2% | -0.6% | +11.1% | -0.4% | -0.3% |
| Jun 5 | Cantor Fitzgerald | Maintains | Overweight → Overweight | — | $7.55 | $8.06 | +6.8% | +10.3% | -3.6% | -0.5% | +0.3% | -4.0% |
| May 15 | H.C. Wainwright | Maintains | Buy → Buy | — | $6.93 | $7.24 | +4.5% | +5.9% | +1.6% | -0.8% | -1.9% | -0.1% |
| Sep 17 | Wedbush | Maintains | Outperform → Outperform | — | $8.40 | $8.46 | +0.7% | -2.1% | +1.0% | -0.8% | -0.7% | -0.4% |
| Mar 12 | Wedbush | Maintains | Outperform → Outperform | — | $9.40 | $9.51 | +1.2% | -1.4% | +1.2% | +0.5% | -0.2% | +1.7% |
| Feb 20 | H.C. Wainwright | Maintains | Buy → Buy | — | $9.01 | $9.33 | +3.6% | +1.1% | +2.2% | -1.9% | +0.3% | +3.7% |
| Date | Insider | Title | Type | Shares | Price | Value | Owned After | D1% | D5% |
|---|---|---|---|---|---|---|---|---|---|
| May 11, 2026 | RALLIS CHRIS A | — | Sell | 8,346 | $7.04 | $59K | 63,077 | — | — |
| May 1, 2026 | Raykov Rosty | — | Sell | 10,781 | $6.47 | $70K | 121,451 | +1.68% | +0.43% |
8-K · 8.01
!! High
Fennec Pharmaceuticals Inc. -- 8-K 8.01: Material Event / Announcement
Fennec Pharmaceuticals disclosed a material announcement via press release, though the specific details require reviewing the attached exhibit for investor impact assessment.
Apr 22
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
University of Arizona initiating a clinical study of Fennec's PEDMARK in adult cancer patients could expand the drug's market addressable population and validate efficacy beyond its approved pediatric indication, potentially driving future revenue growth.
Apr 7
8-K
Unknown — 8-K Filing
Fennec reported 2025 results and provided a business update, likely including revenue performance, cash position, and pipeline progress that will determine whether the specialty pharma company can sustain operations and advance its drug candidates.
Mar 24
8-K · 8.01
!! High
Unknown — 8-K 8.01: Material Event / Announcement
Fennec Pharmaceuticals settled a material dispute, likely resolving legal or financial obligations that removes uncertainty and allows management focus on core operations and product development.
Mar 16
8-K · 8.01
!! High
Fennec Pharmaceuticals Inc. -- 8-K 8.01: Material Event / Announcement
Fennec Pharmaceuticals disclosed a material event through press release filing without specifying the announcement details in this 8-K submission.
Mar 4
8-K · 8.01
!! High
Fennec Pharmaceuticals Inc. -- 8-K 8.01: Material Event / Announcement
Fennec Pharmaceuticals' PEDMARK demonstrated feasibility and tolerability when administered six hours post-cisplatin in adult patients, potentially expanding its therapeutic applicability beyond its current pediatric indication.
Feb 20
Data updated apr 25, 2026 8:52am
· Source: massive.com